并发基因改变预测EGFR突变晚期非小细胞肺癌靶向治疗进展
这项回顾性队列研究利用2014年1月至2017年5月的panel测序数据及至2018年2月的临床结局,分析一线或二线EGFR-TKI治疗前共发生的基因改变与预后的关系。队列1中TP53改变与更差的无进展生存期独立相关;队列2中TP53、RB1、PTEN改变及MDM2扩增均与更差的无进展生存期独立相关。
要点
- 队列1中TP53改变与更差PFS独立相关(HR 2.02,95%CI 1.04-3.93,p=0.038)。
- 队列2中TP53、RB1、PTEN改变及MDM2扩增均与更差PFS独立相关。
- RB1突变者中位PFS为1.9个月,野生型为11.7个月(p<0.001)。
核心结论
- 通过panel测序检测到的共发生基因改变与非小细胞肺癌EGFR-TKI治疗的临床结局相关。
研究设计与样本
- 回顾性队列研究,panel测序数据获取时间为2014年1月至2017年5月,临床结局数据收集至2018年2月。
- 队列1纳入一线或二线EGFR-TKI治疗前有panel测序数据的合格患者,共75例(平均[SD]年龄58.5[11.0]岁,女性68.0%)。
- 队列2纳入初始EGFR-TKI失败后接受三代EGFR-TKI治疗且有panel测序数据的合格患者,共82例(平均[SD]年龄57.3[9.1]岁,女性67.1%)。
主要发现
- 队列1多因素分析中,TP53改变与更差PFS独立相关(HR 2.02,95%CI 1.04-3.93,p=0.038)。
- 队列2中,TP53突变与更差PFS显著相关(8.9个月 vs 12.8个月,p=0.029)。
- 队列2中,RB1突变与更差PFS显著相关(中位PFS 1.9个月 vs 11.7个月,p<0.001)。
- 队列2中,PTEN突变与更差PFS显著相关(2.6个月 vs 10.3个月,p=0.001);MDM2扩增与更差PFS相关(6.6个月 vs 10.4个月,p=0.025)。
- 队列2多因素分析中,TP53改变(HR 2.23,95%CI 1.16-4.29,p=0.017)、RB1改变(HR 5.62,95%CI 1.96-16.13,p=0.001)、PTEN改变(HR 5.84,95%CI 1.56-21.85,p=0.009)及MDM2改变(HR 2.46,95%CI 1.02-5.94,p=0.046)均与更差PFS独立相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: EGFR-mutant NSCLC displays diverse outcomes to tyrosine kinase inhibitor (TKI) treatment. Because co-occurring genomic alterations might describe different biological subsets of patients with this cancer, exploring co-occurring genomic alterations that impact patients' outcomes using a comprehensive gene panel is potentially important. METHODS: This retrospective cohort study was conducted with the panel-sequencing data acquired from January 2014 to May 2017, and clinical outcome data collected until February 2018. This study includes all eligible patients who possess panel-sequencing data before treatment with first-/second-generation EGFR-TKIs (cohort 1) or third-generation EGFR-TKIs following initial EGFR-TKI failure (cohort 2). RESULTS: Seventy-five patients (mean [SD] age, 58.5 [11.0] years; 68.0% women) were included in cohort 1, and 82 patients (mean [SD] age, 57.3 [9.1] years; 67.1% women) were included in cohort 2. In cohort 1, alterations in TP53 were independently associated with worse progression-free survival (PFS) (hazard ratio [HR]: 2.02; 95% confidence interval [CI]: 1.04-3.93; p = 0.038) in multivariate analysis. In cohort 2, TP53 mutation was associated with significantly worse PFS (8.9 versus 12.8 months; p = 0.029). RB1 mutation was significantly associated with worse (median PFS, 1.9 versus 11.7 months; p < 0.001). PTEN mutation was associated with significantly worse PFS (2.6 versus 10.3 months; p = 0.001). MDM2 amplification was associated with worse PFS (6.6 versus 10.4 months; p = 0.025). In cohort 2, multivariate analysis revealed that alterations in TP53 (HR: 2.23; 95% CI: 1.16-4.29; p = 0.017), RB1 (HR: 5.62; 95% CI: 1.96-16.13; p = 0.001), PTEN (HR: 5.84; 95% CI: 1.56-21.85; p = 0.009), and MDM2 (HR: 2.46; 95% CI: 1.02-5.94; p = 0.046) were independently associated with worse PFS. CONCLUSIONS: Co-occurring genomic alterations detected by panel sequencing are associated with the clinical outcomes of EGFR-TKI treatment in NSCLC.
引用
- Kim Y, Lee B, Shim JH, et al. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. J Thorac Oncol. 2018. PMID: 30391576. doi:10.1016/j.jtho.2018.10.150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。